Assignee
REGENERON PHARMA
US·1,347 granted patents·983 pending applications·17,262 citations·filing 1990–2025
Top patents by PatentIndex Score
2,330 records- 0199US11730794B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2020·Granted Aug 22, 2023·8 cites·41 claims
- 0299US11707506B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Jul 25, 2023·5 cites·42 claims
- 0399US11559564B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2022·Granted Jan 24, 2023·5 cites·29 claims
- 0499US11253572B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2021·Granted Feb 22, 2022·11 cites·30 claims
- 0599US11084865B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2020·Granted Aug 10, 2021·14 cites·64 claims
- 0699US10888601B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2019·Granted Jan 12, 2021·14 cites·47 claims
- 0799US10857205B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Dec 8, 2020·14 cites·3 claims
- 0899US10828345B2Use of a VEGF antagonist to treat angiogenic eye disordersREGENERON PHARMA·Filed 2018·Granted Nov 10, 2020·19 cites·11 claims
- 0999US10464992B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Nov 5, 2019·60 cites·18 claims
- 1099US10412940B2Mice expressing a limited immunoglobulin light chain repertoireREGENERON PHARMA·Filed 2018·Granted Sep 17, 2019·38 cites·15 claims
- 1199US10406226B2Method of manufacturing VEGF antagonist fusion proteinsREGENERON PHARMA·Filed 2017·Granted Sep 10, 2019·70 cites·4 claims
- 1299US10400025B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·54 cites·15 claims
- 1399US10392430B2Methods of making nucleic acid molecules encoding modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2017·Granted Aug 27, 2019·37 cites·2 claims
- 1499US9914763B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Mar 13, 2018·56 cites·12 claims
- 1599US9844212B2Human lambda light chain miceREGENERON PHARMA·Filed 2017·Granted Dec 19, 2017·15 cites·30 claims
- 1699US9708386B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2015·Granted Jul 18, 2017·41 cites·5 claims
- 1799US9657102B2Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereofREGENERON PHARMA·Filed 2013·Granted May 23, 2017·125 cites·12 claims
- 1899US9636400B2VEGF specific fusion protein antagonist formulationsREGENERON PHARMA·Filed 2016·Granted May 2, 2017·59 cites·27 claims
- 1999US9580489B2VEGF antagonist formulations suitable for intravitreal administrationREGENERON PHARMA·Filed 2016·Granted Feb 28, 2017·67 cites·29 claims
- 2099US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 2199US9340594B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2014·Granted May 17, 2016·73 cites·12 claims
- 2299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 2399US9226484B2Human lambda light chain miceREGENERON PHARMA·Filed 2015·Granted Jan 5, 2016·31 cites·7 claims
- 2499US9206263B2Method of making antibodies using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·33 cites·35 claims
- 2599US9206262B2Method of cloning a lambda light chain variable domain using a human lambda light chain mouseREGENERON PHARMA·Filed 2015·Granted Dec 8, 2015·20 cites·15 claims
- 2699US9163092B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 20, 2015·36 cites·20 claims
- 2799US9150662B2Hybrid light chain miceREGENERON PHARMA·Filed 2015·Granted Oct 6, 2015·31 cites·20 claims
- 2899US9066502B2Hybrid light chain miceREGENERON PHARMA·Filed 2013·Granted Jun 30, 2015·36 cites·13 claims
- 2999US9029628B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted May 12, 2015·37 cites·21 claims
- 3099US9006511B2Human lambda light chain miceREGENERON PHARMA·Filed 2013·Granted Apr 14, 2015·45 cites·7 claims
- 3199US8802107B2VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2013·Granted Aug 12, 2014·65 cites·18 claims
- 3299US8735095B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2012·Granted May 27, 2014·103 cites·29 claims
- 3399US8697940B2ADAM6 miceREGENERON PHARMA·Filed 2013·Granted Apr 15, 2014·114 cites·21 claims
- 3499US8343737B2Cell culture compositions capable of producing a VEGF-binding fusion polypeptideREGENERON PHARMA·Filed 2011·Granted Jan 1, 2013·73 cites·12 claims
- 3599US8043617B2Human antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2009·Granted Oct 25, 2011·91 cites·9 claims
- 3699US8029791B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2008·Granted Oct 4, 2011·73 cites·9 claims
- 3799US7807164B2Lyophilized VEGF antagonist formulations for intravitreal administrationREGENERON PHARMA·Filed 2009·Granted Oct 5, 2010·83 cites·9 claims
- 3899US7704500B2Methods of inhibiting ascites formation with modified chimeric VEGF polypeptidesREGENERON PHARMA·Filed 2008·Granted Apr 27, 2010·59 cites·8 claims
- 3999US7608693B2High affinity human antibodies to human IL-4 receptorREGENERON PHARMA·Filed 2008·Granted Oct 27, 2009·158 cites·10 claims
- 4099US7582298B2High affinity antibodies to human IL-6 receptorREGENERON PHARMA·Filed 2007·Granted Sep 1, 2009·390 cites·7 claims
- 4199US7435553B2Isolating cells expressing secreted proteinsREGENERON PHARMA·Filed 2006·Granted Oct 14, 2008·104 cites·15 claims
- 4299US7396664B2VEGF-binding fusion proteins and nucleic acids encoding the sameREGENERON PHARMA·Filed 2005·Granted Jul 8, 2008·171 cites·11 claims
- 4399US7374757B2Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2004·Granted May 20, 2008·137 cites·7 claims
- 4499US7374758B2Modified chimeric polypeptides with improved pharmacokinetic properties and methods of using thereofREGENERON PHARMA·Filed 2004·Granted May 20, 2008·124 cites·3 claims
- 4599US7306799B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 11, 2007·140 cites·11 claims
- 4699US7303747B2Use of VEGF inhibitors for treatment of eye disordersREGENERON PHARMA·Filed 2005·Granted Dec 4, 2007·112 cites·6 claims
- 4799US7205148B2Genome mutation by intron insertion into an embryonic stem cell genomeREGENERON PHARMA·Filed 2004·Granted Apr 17, 2007·93 cites·9 claims
- 4899US7105348B2Methods of modifying eukaryotic cellsREGENERON PHARMA·Filed 2002·Granted Sep 12, 2006·355 cites·15 claims
- 4999US7087411B2Fusion protein capable of binding VEGFREGENERON PHARMA·Filed 2003·Granted Aug 8, 2006·345 cites·16 claims
- 5099US7070959B1Modified chimeric polypeptides with improved pharmacokinetic propertiesREGENERON PHARMA·Filed 2000·Granted Jul 4, 2006·196 cites·15 claims
Showing the top 50 of 2,330 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →